Education
About Us
Working with TipRanks
Follow Us
Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
SION Analyst Ratings
Moderate Buy
5 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SION Stock 12 Month Forecast
Average Price Target
$46.20
▲(5.72% Upside)
| Highest Price Target$60.00 | Average Price Target$46.20 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$60
Buy
37.30%
Upside
Initiated
12/23/25
Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic FibrosisIniang Coverage: Don't (Mis)Fold of CFTR We are inia ng c overage on Sionna Therapeucs (Nasdaq: SION) under our an OUTPERFORM rang and price t arget of $60/share. Sionna is a clinical-stage pharmaceuc al company focused on unlocking the potenal of NBD1 domain s tabilizaon t o restore protein funcon in pa en ts with cysc fibr osis (CF). ~85% of CF paen ts carry at least one allele of the F508del mutaon, which occur s within the CFTR NBD1 domain, generang a thermally uns table protein, prevenng pr oper folding, trafficking, and funcon a t physiological temperatures, which contributes to CF pathophysiology. In theory, Sionna’s differena ted approach to stabilizing CFTR closer to the source of the destabilizing mutaon has pot enal t o drive best-in- class efficacy.
JonesTrading
$52
Buy
18.99%
Upside
Reiterated
12/15/25
RBC Capital
$24
Sell
-45.08%
Downside
Reiterated
12/04/25
TD Cowen
Buy
―
Reiterated
11/05/25
Guggenheim
$45
Buy
2.97%
Upside
Reiterated
08/11/25
Stifel Nicolaus
$32
Buy
-26.77%
Downside
Reiterated
05/14/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$60
Buy
37.30%
Upside
Initiated
12/23/25
Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic FibrosisIniang Coverage: Don't (Mis)Fold of CFTR We are inia ng c overage on Sionna Therapeucs (Nasdaq: SION) under our an OUTPERFORM rang and price t arget of $60/share. Sionna is a clinical-stage pharmaceuc al company focused on unlocking the potenal of NBD1 domain s tabilizaon t o restore protein funcon in pa en ts with cysc fibr osis (CF). ~85% of CF paen ts carry at least one allele of the F508del mutaon, which occur s within the CFTR NBD1 domain, generang a thermally uns table protein, prevenng pr oper folding, trafficking, and funcon a t physiological temperatures, which contributes to CF pathophysiology. In theory, Sionna’s differena ted approach to stabilizing CFTR closer to the source of the destabilizing mutaon has pot enal t o drive best-in- class efficacy.
JonesTrading
$52
Buy
18.99%
Upside
Reiterated
12/15/25
RBC Capital
$24
Sell
-45.08%
Downside
Reiterated
12/04/25
TD Cowen
Buy
―
Reiterated
11/05/25
Guggenheim
$45
Buy
2.97%
Upside
Reiterated
08/11/25
Stifel Nicolaus
$32
Buy
-26.77%
Downside
Reiterated
05/14/25
Best Analysts Covering Sionna Therapeutics, Inc.
1 Month
xxx
Success Rate
3/3 ratings generated profit
Average Return
+14.57%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +14.57% per trade.
3 Months
xxx
Success Rate
5/5 ratings generated profit
Average Return
+50.16%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +50.16% per trade.
1 Year
Success Rate
2/2 ratings generated profit
Average Return
+219.60%
reiterated a buy rating 8 months ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +219.60% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
Average Return
+219.60%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +219.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SION Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
2
3
2
1
0
Buy
3
2
2
4
8
Hold
0
1
1
2
1
Sell
0
0
0
0
2
Strong Sell
0
0
0
0
0
total
5
6
5
7
11
Each month's total comprises the sum of three months' worth of ratings.
SION Financial Forecast
SION Stock Forecast FAQ
What is SION’s average 12-month price target, according to analysts?
Based on analyst ratings, Sionna Therapeutics, Inc.’s 12-month average price target is 46.20.
What is SION’s upside potential, based on the analysts’ average price target?
Sionna Therapeutics, Inc. has 5.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SION a Buy, Sell or Hold?
Sionna Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 5 buy ratings, 0 hold ratings and 1 sell ratings.
What is Sionna Therapeutics, Inc.’s price target?
The average price target for Sionna Therapeutics, Inc. is 46.20. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $24.00. The average price target represents 5.72% Increase from the current price of $43.7.
The highest analyst price target is $60.00 ,the lowest forecast is $24.00. The average price target represents 5.72% Increase from the current price of $43.7.
What do analysts say about Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of SION?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.